FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
06/21/2022
Back to search
Official data from USPTO
RZNOMICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
31
Latest update
06/21/2022
Classification
Registered
Trademark type
Combined
Nice classes
5, 42
Filing date
11/13/2020
Registration date
12/14/2021
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/14/2021
Last transaction
12/14/2021
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
03
Owner location
KR
Examiner
FOSTER, ALEXANDRA M.
Law office
M80
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the stylized wording "RZNOMICS" with "R", "NOM", and "CS" in grey, "Z" in red, and the "I" being formed by a grey, yellow, light grey, and red helix with a red circle forming the dot.
Holders and representatives
Holders
Rznomics Inc.
Representatives
Kisuk Lee Harness, Dickey & Pierce, PLC
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Ophthalmic preparations; pharmaceutical products for the treatment of viral and infectious diseasefor the treatment of cancer; pharmaceutical products for the treatment of cancer; pharmaceuticals for the treatment of cancer diseaseneurodegenerative diseaseneurodevelopmental disordereye diseasemuscular diseaseinfectious diseasecardiovascular diseasegastrointestinal diseaseblood diseasemetabolic diseaseimmune diseasegenetic disease; pharmaceutical preparations acting on the central nervous system for the treatment of dementiaAlzheimer's diseaseParkinson's diseaseHuntington's diseaseneuromuscular disordersneurodevelopmental disordersneurovascular disease; anti-cancer preparations; cardiovascular pharmaceuticals; pharmaceutical preparations for immunity adjustment; pharmaceutical preparations for the use in hematology; anti-diabetic pharmaceuticals; pharmaceutical products for the treatment of infectious disease; anti-dermoinfectives; pharmaceutical preparations for the treatment of kidney disease; pharmaceutical agents affecting peripheral nervous system; pharmaceutical preparations in the nature of autonomic drugs for medical purposes; pharmaceutical products for treating respiratory disease; pharmaceutical preparations for treating epidermal problems; viral vaccines; anti-viral agentsanti-viral disinfectants; pharmaceutical and veterinary preparations for the treatment of cancer diseaseneurodegenerative diseaseeye diseasemuscular diseaseinfectious diseasecardiovascular diseasegastrointestinal diseaseblood diseasemetabolic diseaseimmune diseasegenetic disease
Class 42
Research and development of vaccines and medicines; drug discovery services; scientific research for medical purposes in the field of cancerous disease; scientific research for medical purposes in the area of cancerous disease; research and development in the fields of pharmaceutical and biotechnology; testinginspection or research of pharmaceuticalscosmetics or foodstuff; pharmaceutical products development; research on the subject of pharmaceuticals; clinical studies of medicinesclinical research in the field of cancer therapyneurodegenerative disease therapyneurodevelopmental disorder therapyeye disease therapymuscular disease therapyinfectious disease therapycardiovascular disease therapygastrointestinal disease therapyblood disease therapymetabolic disease therapyimmune disease therapygenetic disease therapyradiologychemotherapy; medical research services for assessing the efficiency of pharmaceuticals; pharmaceutical drug development services; scientific research in the field of pharmacy; consultancy pertaining to pharmacology; medicine researchresearch and development of vaccines and medicines; testing of pharmaceuticals; research in the field of medical products; providing information on the testinspectionresearch of medical products; consultation and providing information in the fields of pharmacology; industrial research in the fields of medicinehealth and pharmacology; analysis of human tissues for medical research
Publications
History of USPTO decisions and trademark events.
31 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
05/27/2022
FIMP
FINAL DISPOSITION PROCESSED
05/27/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
03/14/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
12/14/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/12/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/28/2021
PUBO
PUBLISHED FOR OPPOSITION
09/28/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/08/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/24/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
08/24/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
08/24/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
08/24/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
08/24/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/24/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/23/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/23/2021
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
08/23/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
08/23/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
08/23/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
08/23/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
08/23/2021
RFNT
REFUSAL PROCESSED BY IB
05/23/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
04/28/2021
RFRR
REFUSAL PROCESSED BY MPU
04/28/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
04/28/2021
CNRT
NON-FINAL ACTION WRITTEN
04/27/2021
DOCK
ASSIGNED TO EXAMINER
04/24/2021
MAFR
APPLICATION FILING RECEIPT MAILED
01/02/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/29/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/24/2020
Continuous trademark protection
Get notified about every new filing that threatens RZNOMICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.